Lonza enters viral vaccine market
Acquires Vivante, a manufacturer of GMP viral-based therapeutics
Lonza, a Swiss supplier of services and fine chemicals to the pharmaceutical industry, has entered the viral based-manufacturing market with the purchase of Vivante GMP Solutions. The acquisition broadens Lonza’s biologics custom services for the growing viral vaccine and gene therapy markets.
Vivante, based in Houston, Texas, US, specialises in viral-based manufacturing technologies.
Lonza said Vivante’s viral-vaccine production services would be enhanced by Lonza’s expertise in expression technologies and large-scale manufacturing platforms.
The company added that Vivante’s experience with the supply of viral vector-based products would complement Lonza’s growing cellular and gene therapy process development and manufacturing capabilities.
David Enloe, Vivante’s founder, president and ceo, said: ‘We could not be happier with the opportunity to be at the forefront of Lonza’s expansion into the viral vaccine and vector market. We believe that the combination of Vivante’s expertise with the technical know-how, financial resources, and global reach that Lonza offers will be a tremendous advantage for our clients.’
Vivante will operate as Lonza’s Viral-based Therapeutics Business.
